NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1194353490
Verify on CMS → Amita Risbud
Endocrinology, Diabetes & Metabolism Physician in San Francisco, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 8,078 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
421
Medicare Part D claims · 89 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
34%
generic claims · 60% brand-name · higher generic rates reduce patient out-of-pocket costs
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Amita Risbud filed 421 Medicare Part D claims in 2024 as an Endocrinology, Diabetes & Metabolism Physician in San Francisco, California, prescribing 34% generic.
- 421
- Part D claims, 2024
- 34%
- generic prescribing
- Likely
- board-certified (heuristic)
- ≥61st
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Amita Risbud
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1194353490), first enumerated 03/31/2020.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 421 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- State context
State board disciplinary context
California statewide board action statistics are published annually — these figures describe aggregate state activity, not Amita Risbud's individual license status. Verify directly with the state medical board.
Source: MBC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1194353490 · Endocrinology, Diabetes & Metabolism Physician
NPI-10 · ENUM-RECENT · TAX-MID · RX-LIGHT · BOOK-LIGHT · PHOTO-ENUM
- NPI-10 1194353490
- ENUM-RECENT 2020
- TAX-MID 8K Endocrinology, Diabetes
- RX-LIGHT 421
- BOOK-LIGHT 890 in California
- PHOTO-ENUM Adelina Priscu, MD · 2020
Amita Risbud's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
421 ≥ 61st percentile 61% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
✓
Board certification likely (heuristic, not verified)
Amita Risbud practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Amita Risbud?
Quality data not reportedPrimary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
421 85% vs specialty avg
Specialty distribution in California
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among California providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Endocrinology, Diabetes & Metabolism Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1194353490 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Gender | Female |
| NPI Issued | 03/31/2020 |
Hospital and facility affiliations
Facilities where Amita Risbud bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Sutter Bay Medical Foundation
San Francisco, CA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Amita Risbud. To verify Amita Risbud's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
Amita Risbud - brand share 60.0%
Endocrinology, Diabetes & Metabolism Physician average
60% brand-name claims vs 34% generic, on 421 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
421
Total Claims
$199K
Total Drug Cost
89
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 782.2
- Total Day Supply
- 22,921
- Brand vs Generic
- 60% brand / 34% generic
- Brand Drug Cost
- $195K
- Generic Drug Cost
- $2K
Patient Demographics
- Average Patient Age
- 74.2 years
- Avg HCC Risk Score
- 2.06
- Gender Split
- 61% female / 39% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Amita Risbud prescribes most
Top Medicare Part D drugs by claim count, 2024
- Ozempic
Ozempic
81 claims
- Levothyroxine Sodium
Levothyroxine Sodium
43 claims
- Mounjaro 19
Mounjaro
19 claims
- Atorvastatin Calcium 18
Atorvastatin Calcium
18 claims
- Metformin Hcl 18
Metformin Hcl
18 claims
- Jardiance 17
Jardiance
17 claims
- Nano 2nd Gen Pen N… 16
Nano 2nd Gen Pen Needle
16 claims
- Januvia 14
Januvia
14 claims
| Drug | Claims |
|---|---|
| Ozempic Semaglutide | 81 |
| Levothyroxine Sodium | 43 |
| Mounjaro Tirzepatide | 19 |
| Atorvastatin Calcium | 18 |
| Metformin Hcl | 18 |
| Jardiance Empagliflozin | 17 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 16 |
| Januvia Sitagliptin Phosphate | 14 |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | 12 |
| Amlodipine Besylate | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in CA →
All providers in California →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Amita Risbud fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
8,078
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,739
Avg Claims per Provider
Amita Risbud's 421 claims are below the specialty average of 2,739.
Nationwide Endocrinology, Diabetes & Metabolism Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Risbud, both outside California so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2020)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Risbud.
One of 890 Endocrinology, Diabetes & Metabolism Physician providers enrolled in California, 5 are shown here.
Dr. Anita Abraham
M.D.
Stockton, CA
Dr. Sallie Adams
M.D.
Roseville, CA
Ananta Addala
Palo Alto, CA
Dr. Helen Adelberg
M.D.
Encino, CA
Dr. David Aftergood
MD
Beverly Hills, CA
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Amita Risbud's specialty? ▼
Amita Risbud specializes in Endocrinology, Diabetes & Metabolism Physician and practices in San Francisco, California.
How much does Amita Risbud prescribe under Medicare Part D? ▼
In 2024, Amita Risbud wrote 421 Medicare Part D claims totaling $199K in drug costs for 89 beneficiaries.
Where is Amita Risbud located? ▼
Amita Risbud is located at 1100 VAN NESS AVE, San Francisco, CA, 94109. Phone: (415) 600-0110.
What is Amita Risbud's NPI number? ▼
Amita Risbud's National Provider Identifier (NPI) is 1194353490, issued on 03/31/2020.
Does Amita Risbud prescribe more brand-name or generic drugs? ▼
Amita Risbud's prescribing is 60% brand-name and 34% generic drugs by claim count, with $195K in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 8,078 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,739 Medicare Part D claims per year.
What drugs does Amita Risbud prescribe most often? ▼
Based on 2024 Medicare Part D data, Amita Risbud's most frequently prescribed drugs include Ozempic, Levothyroxine Sodium, Mounjaro. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Amita Risbud accept Medicare? ▼
Amita Risbud appears in CMS Medicare data with 421 Part D claims and 89 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Amita Risbud's credentials? ▼
Amita Risbud's NPI is 1194353490. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.